Antibody-Drug Conjugates in Solid Tumors
Solid tumors account for approximately 90% of all types of cancer. For many tumor types, the availability of effective treatment options is limited and new targeted approaches that offer the potential for long-term survival are warranted. Antibody-drug conjugates (ADCs) are a new class of drugs that...
Saved in:
| Main Authors: | Ilaria Colombo, Alfred Zippelius |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2022-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2022.11.062 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody-Drug Conjugates in Ovarian Cancer: Promises and Challenges
by: Marta Nerone, et al.
Published: (2023-10-01) -
Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
by: Wenjun Fang, et al.
Published: (2025-12-01) -
Editorial: Antibody-drug conjugates in solid and hematologic malignancies
by: Khalil Saleh, et al.
Published: (2025-08-01) -
Engineering heavy chain antibody‐drug conjugates against solid tumors for a one‐shot kill
by: Xue Liu, et al.
Published: (2024-12-01) -
Antibody drug conjugates
by: Stalin Bala, et al.
Published: (2020-01-01)